banner

Investors

At Acadia, we remain deeply committed to providing important new therapies to patients and delivering value for our stockholders. Our Investor Center is designed to provide you with convenient access to company information.

Recent News

04/05/21
Summary ToggleAcadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
- Conference call and webcast to be held today at 8:00 a.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Apr. 5, 2021-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Company has received a Complete Response Letter (CRL) from the U.S.
03/08/21
Summary ToggleAcadia Pharmaceuticals Provides Regulatory Update on Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
- Conference call and webcast to be held today at 5:00 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Mar. 8, 2021-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Company received a notification from the U.S. Food and Drug Administration (FDA) on March 3, 2021 , stating that,
02/24/21
Summary ToggleAcadia Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
- Full year 2020 net sales grew to $441.8 million , a 30% increase over 2019 - Upcoming PDUFA action date of April 3, 2021 for supplemental New Drug Application for pimavanserin for the treatment of hallucinations and delusions associated with dementia-related psychosis SAN DIEGO --(BUSINESS
2020 | 2019 | 2018 | Archive
Webcasts
Click here for webcast
Click here for webcast
Acadia Pharmaceuticals Conference Call
 04/05/21 at 8:00 AM EDT

Stock Quote

Exchange
Price
Change (%)  
Volume
04/17/21 4:49 pm EDT
Data Provided by Refinitiv.
Minimum 15 minutes delayed.
Refresh quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.